19020-Lung Cancer-NA-108

Lung Cancer

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

  • Details

ClinicalTrials.gov ID: NCT03515837
Diagnosis Type: NA
USOR Number:

  • Address

7777 Forest Lane, Suite D400
Dallas, TX 75230
P: (972) 566-6647

Search by practice name, trial titles, indicators and specific disease types.